Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

This study (STARLET) tests a combination of niraparib (a PARP inhibitor that prevents cancer cells from repairing their DNA) and dostarlimab (an immunotherapy) in patients with advanced cancer that has spread to the brain, focusing on cancers with certain DNA repair defects. **You may be eligible if...** - You are 18 or older with active, progressing brain metastases - You have advanced BRCA1/2-mutated cancer, HRR-deficient cancer, small cell lung cancer, non-small cell lung cancer, or triple-negative breast cancer - Your cancer has a mutation in one of several DNA repair genes (BRCA1/2, ATM, PALB2, CHEK1/2, and others) **You may NOT be eligible if...** - You have had prior PARP inhibitor therapy - Your brain metastases are well-controlled and not progressing - You have autoimmune conditions requiring systemic treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.